Nonalcoholic fatty liver disease: Current concepts, epidemiology and management strategies

European Journal of Gastroenterology and Hepatology

Volumn 30, Issue 10, 2018, Pages 1103-1115

  Tomic, Dunya ^a   Kemp, William W ^a   Roberts, Stuart K ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

fatty liver; liver diseases; nonalcoholic fatty liver disease; review

Indexed keywords

ALPHA TOCOPHEROL; URSODEOXYCHOLIC ACID;

BARIATRIC SURGERY; BODY WEIGHT LOSS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIET THERAPY; DIETARY PATTERN; HUMAN; INCIDENCE; INSULIN RESISTANCE; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRANSIENT ELASTOGRAPHY; COMPLICATION; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE;

DIABETES MELLITUS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIFE STYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RISK FACTORS;

EID: 85053917596     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000001235     Document Type: Review

References (166)

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142:1592-1609.
2. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10:686-690.
3. Adam R, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57:675-688.
4. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015; 148:547-555.
5. Adams LA, Lymp JF St, Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005; 129:113-121.
6. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53:372-384.
7. Powell EE, Jonsson JR, Clouston AD. Steatosis: Co-factor in other liver diseases. Hepatology 2005; 42:5-13.
8. Huang PL. A comprehensive definition for metabolic syndrome. DNM Dis Models Mech 2009; 2:231-237.
9. DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, et al. Nonalcoholic fatty liver disease and serum lipoproteins: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2013; 227:429-436.
10. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 35:898-904.
11. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979; 67:811-816.
12. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30:1356-1362.
13. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118:1117-1123.
14. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000; 132:112-117.
15. Frith J, Day CP, Robinson L, Elliott C, Jones DEJ, Newton JL. Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J Hepatol 2010; 52:112-116.
16. Caldwell SH, Crespo DM. The spectrum expanded: Cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40:578-584.
17. Aron-Wisnewsky J, Minville C, Tordjman J, Lévy P, Bouillot JL, Basdevant A, et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol 2012; 56:225-233.
18. Kral JG, Schaffner F, Pierson RN Jr, Wang J. Body fat topography as an independent predictor of fatty liver. Metab Clin Exp 1993; 42:548-551.
19. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990; 12:1106-1110.
20. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121:710-723.
21. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56:943-951.
22. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology 2008; 48:792-798.
23. Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Dalla Man C, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci USA 2006; 103:18273-18277.
24. El-Karaksy HM, Anwar G, Esmat G, Mansour S, Sabry M, Helmy H, et al. Prevalence of hepatic abnormalities in a cohort of Egyptian children with type 1 diabetes mellitus. Pediatr Diabetes 2010; 11:462-470.
25. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, et al. Long term nutritional intake and the risk for nonalcoholic fatty liver disease (NAFLD): A population based study. J Hepatol 2007; 47:711-717.
26. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48:993-999.
27. Sookoian S, Castanõ GO, Pirola CJ. Modest alcohol consumption decreases the risk of nonalcoholic fatty liver disease: A meta-analysis of 43 175 individuals. Gut 2014; 63:530-532.
28. Loomba R, Yang HI, Su J, Brenner D, Barrett-Connor E, Iloeje U, et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: A prospective cohort study. Am J Epidemiol 2013; 177:333-342.
29. Catalano D, Martines GF, Tonzuso A, Pirri C, Trovato FM, Trovato GM. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2010; 55:3200-3206.
30. Struben VMD, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000; 108:9-13.
31. Valenti L, Al-Serri A, Daly AK, Enrico G, Rametta R, Dongiovanni P, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51:1209-1217.
32. Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio A, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology (Baltimore, MD) 2010; 52:1274-1280.
33. Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015; 61:506-514.
34. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesityassociated liver disease. J Clin Endocrinol Metab 2008; 93 (Suppl 1): S74-s80.
35. Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010; 51:1593-1602.
36. Browning JD. Statins and hepatic steatosis: Perspectives from the Dallas heart study. Hepatology 2006; 44:466-471.
37. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57:1357-1365.
38. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008; 47:1947-1954.
39. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology 2005; 42:44-52.
40. Van Der Voort EAM, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HLA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol 2014; 70:517-524.
41. Kanerva N, Sandboge S, Kaartinen NE, Männistö S, Eriksson JG. Higher fructose intake is inversely associated with risk of nonalcoholic fatty liver disease in older Finnish adults. Am J Clin Nutr 2014; 100:1133-1138.
42. Perez M, Gonzáles L, Olarte R, Rodríguez NI, Tabares M, Salazar JP, et al. Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population. Prev Med 2011; 52:174-177.
43. Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérezayuso RM, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2009; 29:82-88.
44. Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012; 56:605-613.
45. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143:722-728.
46. Ratziu V, Cadranel JF, Serfaty L, Denis J, Renou C, Delassalle P, et al. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J Hepatol 2012; 57:376-383.
47. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134:1682-1698.
48. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40:1387-1395.
49. Tarnoki AD, Tarnoki DL, Bata P, Littvay L, Osztovits J, Jermendy G, et al. Heritability of non-alcoholic fatty liver disease and association with abnormal vascular parameters: A twin study. Liver Int 2012; 32:1287-1293.
50. Uauy R, Albala C, Kain J. Obesity trends in Latin America: Transiting from under-to overweight. J Nutr 2001; 131:893s-899s.
51. Leite NC, Villela-Nogueira CA, Pannain VLN, Bottino AC, Rezende GFM, Cardoso CRL, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: Prevalences and correlated factors. Liver Int 2011; 31:700-706.
52. Pereira Lima MLR, Oliveira Mouraõ SC, Costa Diniz MT, Rios Leite VH. Hepatic histopathology of patients with morbid obesity submitted to gastric bypass. Obes Surg 2005; 15:661-669.
53. Sniderman AD, Bhopal R, Prabhakaran D, Sarrafzadegan N, Tchernof A. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. Int J Epidemiol 2007; 36:220-225.
54. Powell EE, Cooksley WG, Hanson R. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 29:664-669.
55. Teli MR, James OFW, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995; 22:1714-1719.
56. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434-438.
57. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990; 85:1349-1355.
58. Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu 1989; 24 (Pt 1):275-302.
59. Luyckx FH, Desaive C, Thiry A, Dewé W, Scheen AJ, Gielen JE, et al. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty. Int J Obes 1998; 22:222-226.
60. Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, et al. NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006; 44:458-465.
61. Marchesini G, Mazzotti A. NAFLD incidence and remission: Only a matter of weight gain and weight loss? J Hepatol 2015; 62:15-17.
62. Cheung O, Kapoor A, Puri P, Sistrun S, Luketic VA, Sargeant CC, et al. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 2007; 46:1091-1100.
63. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: Potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94:1018-1022.
64. Angulo P, Keach JC, Batts KP, Lindor KP. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. J Hepatol 1989; 30:356-362.
65. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42:132-138.
66. Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988; 95:1056-1062.
67. Itoh S, Yougel T, Kanagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987; 82:650-654.
68. Westerbacka J, Cornér A, Tiikkainen M, Tamminen M, Vehkavaara S, Häkkinen AM, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: Implications for sex differences in markers of cardiovascular risk. Diabetologia 2004; 47:1360-1369.
69. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994; 107:1103-1109.
70. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Yao Chang L, McCullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116:1413-1419.
71. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123:745-750.
72. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study. J Hepatol 2009; 51:1061-1067.
73. Mitchell DG. Focal manifestations of diffuse liver disease at MR imaging. Radiology 1992; 185:1-11.
74. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989; 111:473-478.
75. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37:1286-1292.
76. Wu WC, Wu CY, Wang YJ, Hung HH, Yang HI, Kao WY, et al. Updated thresholds for serum alanine aminotransferase level in a largescale population study composed of 34 346 subjects. Aliment Pharmacol Ther 2012; 36:560-568.
77. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137:1-9.
78. Guajardo-Salinas GE, Hilmy A. Prevalence of nonalcoholic fatty liver disease (NAFLD) and utility of FIBROspect II to detect liver fibrosis in morbidly obese hispano-american patients undergoing gastric bypass. Obes Surg 2010; 20:1647-1653.
79. Lin SC, Heba E, Wolfson T. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique. Clin Gastroenterol Hepatol 2015; 13:1337-1345.
80. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled Attenuation Parameter (CAP): A noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012; 32:902-910.
81. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51:433-445.
82. Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013; 58:1930-1940.
83. Bastati N, Feier D, Wibmer A, Traussnigg S, Balassy C, Tamandl D, et al. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: A proof-of-concept study. Radiology 2014; 271:739-747.
84. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149:389. e10-397.e10.
85. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? Hepatology 2010; 51:373-375.
86. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European liver fibrosis panel and exploring simple markers. Hepatology 2008; 47:455-460.
87. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45:846-854.
88. Calès P, Lainé F, Boursier J, Deugnier Y, Moal V, Oberti F, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50:165-173.
89. Wong VWS, Vergniol J, Wong GLH, Foucher J, Chan HLY, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51:454-462.
90. Caste ra L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, et al. Pitfalls of liver stiffness measurement: A 5-year prospective study of 13, 369 examinations. Hepatology 2010; 51:828-8835.
91. Wong VWS, Vergniol J, Wong GLH, Foucher J, Chan AWH, Chermak F, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107:1862-1871.
92. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55:199-208.
93. Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study. Hepatology 2014; 60:1920-1928.
94. Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Ünalp A. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 2008; 48:829-834.
95. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321.
96. Bedossa P, Burt DA, Gouw SHA, Lackner C, Schirmacher P, Terracciano L, et al. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014; 60:565-575.
97. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128:1898-1906.
98. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings. Hepatology 2011; 53:810-820.
99. Petta S, Wong VWS, Cammà C, Hiriart JB, Wong GLH, Vergniol J, et al. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. Aliment Pharmacol Ther 2017; 46:617-627.
100. Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016; 64:1577-1586.
101. Ascha MS, Hanouneh IA, Lopez R, Tamimi TAR, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51:1972-1978.
102. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic Hepatitis B and C: A prospective study of 251 patients. Hepatology 1995; 21:650-655.
103. Brancatelli G, Federle MP, Grazioli L, Carr BI. Hepatocellular carcinoma in noncirrhotic liver: Ct, clinical, and pathologic findings in 39 U.S. residents. Radiology 2002; 222:89-94.
104. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: Insights into the etiology and pathogenesis of liver cancer. Oncogene 2007; 26:2166-2176.
105. Hong TP, Gow P, Fink M, Dev A, Roberts S, Nicoll A, et al. Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. Hepatology 2016; 63:1205-1212.
106. Bralet MP, Régimbeau JM, Pineau P, Dubois S, Loas G, Degos F, et al. Hepatocellular carcinoma occurring in nonfibrotic liver: Epidemiologic and histopathologic analysis of 80 french cases. Hepatology 2000; 32:200-204.
107. De Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes: The verona diabetes study. Diabetes Care 1999; 22:756-761.
108. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10:656-665.
109. Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta Mol Basis Dis 2014; 1842:446-462.
110. Alonso A, Misialek JR, Amiin MA, Hoogeveen RC, Chen LY, Agarwal SK, et al. Circulating levels of liver enzymes and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities cohort. Heart 2014; 100:1511-1516.
111. Targher G, Mantovani A, Pichiri I, Rigolon R, Dauriz M, Zoppini G, et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci 2013; 125:301-309.
112. Hung CS, Tseng PH, Tu CH, Chen CC, Liao WC, Lee YC, et al. Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J Am Heart Assoc 2015; 4:7.
113. Robbins J, Nelson JC, Rautaharju PM, Gottdiener JS. The association between the length of the QT interval and mortality in the cardiovascular health study. Am J Med 2003; 115:689-694.
114. Markus MRP, Baumeister SE, Stritzke J, Dorr M, Wallaschofski H, Volzke H, et al. Hepatic steatosis is associated with aortic valve sclerosis in the general population: The study of health in Pomerania (SHIP). Arterioscler Thromb Vasc Biol 2013; 33:1690-1695.
115. Yasui K, Sumida Y, Mori Y, Mitsuyoshi H, Minami M, Itoh Y, et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 2011; 60:735-739.
116. Yilmaz Y, Alahdab YO, Yonal O, Kurt R, Kedrah AE, Celikel CA, et al. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: Association with liver fibrosis. Metabolism 2010; 59:1327-1330.
117. Kim NH, Park J, Kim SH, Kim YH, Kim DH, Cho GY, et al. Nonalcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 2014; 100:938-943.
118. Ittermann T, Haring R, Wallaschofski H, Baumeister SE, Nauck M, Dörr M, et al. Inverse association between serum free thyroxine levels and hepatic steatosis: Results from the Study of Health in Pomerania. Thyroid 2012; 22:568-574.
119. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99:1408-1413.
120. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12:224-229.
121. Eckel RH. Nonsurgical management of obesity in adults. New Engl J Med 2008; 358:1941-1950.
122. Atkinson RL, Fuchs A, Pastors JG, Saunders JT. Combination of verylow-calorie diet and behavior modification in the treatment of obesity. Am J Clin Nutr 1992; 56 (Suppl):199s-202s.
123. Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC. Short-term weight loss and hepatic triglyceride reduction: Evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 2011; 93:1048-1052.
124. Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013; 59:138-143.
125. George ES, Forsyth A, Itsiopoulos C, Nicoll AJ, Ryan M, Sood S, et al. Practical dietary recommendations for the prevention andmanagement of nonalcoholic fatty liver disease in adults. Adv Nutr 2018; 9:30-40.
126. Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35:76-82.
127. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012; 55:429-436.
128. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011; 106:460-468.
129. Slentz CA, Bateman LA, Willis LH, Shields AT, Tanner CJ, Piner LW, et al. Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT. Am J Physiol Endocrinol Metab 2011; 301:E1033-E1039.
130. Oh S, Shida T, Yamagishi K, Tanaka K, So R, Tsujimoto T, et al. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: A retrospective study. Hepatology 2015; 61:1205-1215.
131. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. New Engl J Med 1996; 335:609-616.
132. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebocontrolled phase 2 study. Lancet 2016; 387:679-690.
133. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31:384.
134. Laurin J, Lindor KD, Crippin JS. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: A pilot study. Hepatology 1996; 39:602-603.
135. Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63:705-712.
136. Anderwald C, Bernroider E, Krššák M, Stingl H, Brehm A, Bischof MG, et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 2002; 51:3025-3032.
137. Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, et al. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: A randomised trial. Diabetologia 2009; 52:723-732.
138. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135:1176-1184.
139. Nicholls SJ, Tuzcu EM, Wolski K, Bayturan O, Lavoie A, Uno K, et al. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: Insights from the periscope (pioglitazone effect on regression of intravascular sonographic coronary obstruction prospective evaluation) study. J Am Coll Cardiol 2011; 57:153-159.
140. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 2009; 373:2125-2135.
141. Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 2010; 12:716-721.
142. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011; 34:916-922.
143. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 2008; 135:100-110.
144. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6:998-1003.
145. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358:893-894.
146. Bhalla K, Hwang B, Dewi RE, Twaddel W, Goloubeva OG, Wong KK, et al. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res 2012; 5:544-552.
147. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-1 level and efficacy of ?-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther 2001; 15:1667-1672.
148. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. J Am Med Assoc 2011; 305:1659-1668.
149. Hayden KM, Welsh-Bohmer KA, Wengreen HJ, Zandi PP, Lyketsos CG, Breitner JCS. Risk of mortality with vitamin e supplements: The Cache County Study. Am J Med 2007; 120:180-184.
150. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia S, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: The selenium and vitamin E cancer prevention trial (SELECT). J Am Med Assoc 2011; 306:1549-1556.
151. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of cardiovascular disease in men: The physicians' health study II randomized controlled trial. J Am Med Assoc 2008; 300:2123-2133.
152. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet 2015; 385:956-965.
153. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study. Am J Gastroenterol 2001; 96 (Suppl):2711-2717.
154. Gulbahar O, Karasu ZA, Ersoz G. Treatment of nonalcoholic steatohepatitis with N-acetylcysteine. Gastroenterology 2000; 118:734-738.
155. Velussi M, Cernigoi AM, Ariella DM, Dapas F, Caffau C, Zilli M. Longterm (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997; 26:871-879.
156. Federico A, Trappoliere M, Tuccillo C, De Sio I, Di Leva A, Del Vecchio Blanco C, et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: Preliminary observations. Gut 2006; 55:901-902.
157. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial. Hepatology 2011; 54:1610-1619.
158. Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 2018; 67:1754-1767.
159. Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-and-, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016; 150:1147-59e5.
160. Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology 2018; 67:549-559.
161. Hutter MM, Schirmer BD, Jones DB, Ko CY, Cohen ME, Merkow RP, et al. First report from the American College of Surgeons Bariatric Surgery Center Network: Laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg 2011; 254:410-422.
162. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. J Am Med Assoc 2012; 307:56-65.
163. Weingarten TN, Swain JM, Kendrick ML, Charlton MR, Schroeder BJ, Lee REC, et al. Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery. Obes Surg 2011; 21:1714-1720.
164. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. New Engl J Med 2007; 357:741-752.
165. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141:1249-1253.
166. Pais R, Barritt A St, Calmus Y, Scatton O, Runge T, Lebray P, et al. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol 2016; 65:1245-1257.